Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06486441 · ClinicalTrials.gov registry record · Phase 3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
A Phase 3 study of Endometrial Cancer, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 3
- Development phase
- 640
- Enrollment target
- 20
- Study locations
NCT06486441 is a Phase 3 study of Endometrial Cancer that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 640 participants, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (23% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06486441, a Phase 3 study of Endometrial Cancer, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 640 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Sacituzumab govitecan-hziy
Study Locations (20)
California
- City of Hope - Duarte
- UC San Diego Medical Center - La Jolla
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center - Los Angeles
- Stanford Women's Cancer Center - Palo Alto
- Kaiser Permanente Medical Center - Vallejo
Florida
- Florida Cancer Specialists - Fort Myers
- University of Florida - Gainesville
- Baptist MD Anderson Cancer Center - Jacksonville
Connecticut
- Hartford HealthCare Cancer Institute at Hartford Hospital - Hartford
- Yale University School of Medicine - New Haven
Georgia
- Winship Cancer Institute, Emory University - Atlanta
- Lewis Cancer & Research Pavilion at St. Joseph's/Candler Health System - Savannah
Illinois
- Northwestern Memorial Hospital - Chicago
- University of Chicago Medical Center - Chicago
Kentucky
- Baptist Health Lexington - Lexington
- Norton Cancer Institute - Louisville
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2029-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06486441
The ClinicalTrials.gov registry entry for NCT06486441 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 640 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (23% higher). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Doxorubicin is the first listed.
NCT06486441 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06486441 about?
NCT06486441 is a clinical study titled "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)". The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives ...
What is the current status of trial NCT06486441?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 640 participants. The study started on 2024-08-28. Estimated completion is 2029-06.
What conditions does trial NCT06486441 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT06486441?
The interventions under investigation include: Doxorubicin (DRUG), Paclitaxel (DRUG), Sacituzumab govitecan-hziy (DRUG).
Who is sponsoring clinical trial NCT06486441?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06486441 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.